在2024年12月7日至10日于美国圣地亚哥举办的第66届美国血液学会（ASH）年会上，一项关于靶向GPRC5D的自体CAR-T细胞疗法BMS-986393（CC-95266）的新疗效数据备受瞩目。该数据针对重度预处理的复发/难治性多发性骨髓瘤（RRMM）患者，展示了这一疗法在临床上的卓越表现，为这类患者带来了新的治疗选择。扫描下方二维码，...
BMS:Current Employment, Current equity holder in publicly-traded company.Chen:Bristol Myers Squibb:Current Employment.Li:Bristol Myers Squibb:Current Employment.Kelly:BMS:Current Employment, Current holder ofstock optionsin a privately-held company.Sarkis:Bristol Myers Squibb:Current Employment, Current ...
基本信息 药品名称 BMS-986393; CC-95266 药品类别 创新药; 生物; 细胞疗法; T细胞; CAR T细胞疗法 靶点 GPRC5D 作用机制 CAR T细胞疗法 药品简介 -- 研发机构 Bristol-Myers Squibb 最高研发阶段 全球: III期临床 中国: 临床前 审评审批类型 -- 外置链接 -- 了解药物更多情报 登录查看 生物...
1,2 Moreover, longitudinal assessment of serum BCMA levels suggested that BMS-986393 produced deep tumor clearance, with the nadir reached within 2 to 3 months of infusion.1 In addition to CC-95266-MM-001, BMS-986393 is under evaluation as monotherapy in a pivotal phase 2 study (NCT06...
Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.